Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	26,902	16,757	16,583	11,592	14,105	11,381
Short-Term Investments	-	63.45	57.81	90.67	57.33	93.4
Cash & Short-Term Investments	26,902	16,821	16,641	11,683	14,163	11,474
Cash Growth	47.80%	1.08%	42.44%	-17.51%	23.43%	2.59%
Accounts Receivable	37,731	33,419	18,584	36,652	31,011	25,721
Other Receivables	-	5,710	8,225	5,743	5,576	4,797
Receivables	37,731	39,130	26,809	42,394	36,588	30,517
Inventory	32,807	30,285	25,131	23,736	24,998	22,768
Prepaid Expenses	-	1,053	266.9	2,275	2,199	2,198
Other Current Assets	17,091	5,667	5,434	27,167	4,876	6,638
Total Current Assets	114,532	92,955	74,281	107,255	82,823	73,596
Property, Plant & Equipment	40,940	38,614	35,375	41,951	46,117	41,756
Long-Term Investments	423.47	605	7,958	472.77	556.64	518.95
Goodwill	806.73	702.66	673.59	736.19	600.19	580.11
Other Intangible Assets	17,305	13,900	12,672	23,427	22,254	22,769
Long-Term Deferred Tax Assets	13,075	11,241	10,497	18,059	16,861	15,347
Other Long-Term Assets	2,937	2,478	2,130	1,816	1,620	1,469
Total Assets	190,020	160,496	143,586	193,717	170,833	156,036
Accounts Payable	29,513	25,795	25,359	20,004	22,887	22,378
Accrued Expenses	-	11,132	12,473	14,427	7,168	6,346
Short-Term Debt	3,587	16,815	8,334	3,500	3,700	5,130
Current Portion of Long-Term Debt	-	-	1,572	1,456	7,286	2,856
Current Portion of Leases	878.53	922.62	886.43	830.39	916.78	742.54
Current Income Taxes Payable	6,258	283.74	2,910	984.98	931.2	501.2
Other Current Liabilities	29,358	4,722	6,652	9,848	4,005	4,057
Total Current Liabilities	69,595	59,670	58,186	51,051	46,894	42,010
Long-Term Debt	5,328	5,127	-	38,521	25,717	38,888
Long-Term Leases	2,448	1,862	1,517	1,771	2,000	2,240
Long-Term Deferred Tax Liabilities	0.59	585.88	2.8	5.14	314.95	287.49
Other Long-Term Liabilities	16,832	4,760	5,405	3,976	1,525	1,967
Total Liabilities	94,204	72,005	65,111	95,324	76,452	85,393
Common Stock	282.2	282.19	282.19	282.17	282.17	282.17
Additional Paid-In Capital	-	16,866	16,866	16,854	16,854	16,854
Retained Earnings	-	89,140	80,160	96,026	93,564	73,791
Comprehensive Income & Other	95,536	-17,793	-18,828	-18,422	-19,834	-20,281
Total Common Equity	95,818	88,494	78,479	94,739	90,866	70,646
Minority Interest	-2.16	-3.71	-3.8	3,653	3,515	-3.54
Shareholders' Equity	95,816	88,491	78,475	98,393	94,381	70,643
Total Liabilities & Equity	190,020	160,496	143,586	193,717	170,833	156,036
Total Debt	12,242	24,727	12,309	46,079	39,620	49,857
Net Cash (Debt)	14,661	-7,906	4,331	-34,396	-25,458	-38,383
Net Cash Per Share	51.94	-28.02	15.35	-121.90	-90.22	-136.03
Filing Date Shares Outstanding	282.18	282.19	282.19	282.17	282.17	282.17
Total Common Shares Outstanding	282.18	282.19	282.19	282.17	282.17	282.17
Working Capital	44,937	33,284	16,095	56,205	35,929	31,586
Book Value Per Share	339.57	313.60	278.11	335.75	322.03	250.37
Tangible Book Value	77,707	73,891	65,134	70,576	68,012	47,297
Tangible Book Value Per Share	275.38	261.85	230.82	250.12	241.04	167.62
Land	-	471.82	461.25	423.45	688.97	581.31
Buildings	-	18,588	17,556	16,069	17,211	13,053
Machinery	-	35,618	32,155	32,052	34,167	28,352
Construction In Progress	-	5,420	4,193	10,658	9,211	12,178

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.